Biomarkers of NAFLD progression: A lipidomics approach to an epidemic 1

Journal of Lipid Research

Volumn 56, Issue 3, 2015, Pages 722-736

  Gorden, D Lee ^a,b   Myers, David S ^b   Ivanova, Pavlina T ^b   Fahy, Eoin ^c   Maurya, Mano R ^c   Gupta, Shakti ^c   Min, Jun ^c   Spann, Nathanael J ^d   McDonald, Jeffrey G ^e   Kelly, Samuel L ^f   Duan, Jingjing ^f   Sullards, M Cameron ^f   Leiker, Thomas J ^g   Barkley, Robert M ^g   Quehenberger, Oswald ^h,i   Armando, Aaron M ⁱ   Milne, Stephen B ^b   Mathews, Thomas P ^b   Armstrong, Michelle D ^b   Li, Chijun ^j   Melvin, Willie V ^a   Clements, Ronald H ^a   Washington, M Kay ^a   Mendonsa, Alisha M ^b   Witztum, Joseph L ^h   Guan, Ziqiang ^j   Glass, Christopher K ^d   Murphy, Robert C ^g   Dennis, Edward A ⁱ   Merrill, Alfred H ^f   Russell, David W ^e   Subramaniam, Shankar ^c,i   Brown, H Alex ^b   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Diagnostic tools; Mass spectrometry; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Phospholipids; Sphingolipids

Indexed keywords

BIOLOGICAL MARKER; GLYCEROPHOSPHOLIPID; MESSENGER RNA; SPHINGOLIPID; STEROL; LIPID;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EPIDEMIC; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LIPIDOMICS; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; URINALYSIS; BLOOD; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON-ALCOHOLIC FATTY LIVER DISEASE; URINE;

ADULT; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84925304914     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P056002     Document Type: Article

References (69)

1. Williams, C. D., J. Stengel, M. I. Asike, D. M. Torres, J. Shaw, M. Contreras, C. L. Landt, and S. A. Harrison. 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 140 : 124-131.
2. Safar Zadeh, E., A. O. Lungu, E. K. Cochran, R. J. Brown, M. G. Ghany, T. Heller, D. E. Kleiner, and P. Gorden. 2013. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J. Hepatol. 59 : 131-137.
3. Cohen, J. C., J. D. Horton, and H. H. Hobbs. 2011. Human fatty liver disease: old questions and new insights. Science. 332 : 1519-1523.
4. Gan, L., S. Chitturi, and G. C. Farrell. 2011. Mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly. Curr. Gerontol. Geriatr. Res. 2011 : 831536.
5. Caldwell, S., and C. Argo. 2010. The natural history of non-alcoholic fatty liver disease. Dig. Dis. 28 : 162-168.
6. Syn, W. K., S. S. Choi, and A. M. Diehl. 2009. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin. Liver Dis. 13 : 565-580.
7. Malhi, H., and G. J. Gores. 2008. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 28 : 360-369.
8. Adams, L. A., O. R. Waters, M. W. Knuiman, R. R. Elliott, and J. K. Olynyk. 2009. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am. J. Gastroenterol. 104 : 861-867.
9. Marchesini, G., E. Bugianesi, G. Forlani, F. Cerrelli, M. Lenzi, R. Manini, S. Natale, E. Vanni, N. Vilanova, N. Melchionda, et al. 2003. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37 : 917-923.
10. Pellicoro, A., P. Ramachandran, J. Iredale, and J. Fallowfield. 2014. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14 : 181-194.
11. Teratani, T., K. Tomita, T. Suzuki, T. Oshikawa, H. Yokoyama, K. Shimamura, S. Tominaga, S. Hiroi, R. Irie, Y. Okada, et al. 2012. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology. 142 : 152-164.
12. Moustafa, T., P. Fickert, C. Magnes, C. Guelly, A. Thueringer, S. Frank, D. Kratky, W. Sattler, H. Reicher, F. Sinner, et al. 2012. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 142 : 140-151.
13. Puri, P., M. M. Wiest, O. Cheung, F. Mirshahi, C. Sargent, H. K. Min, M. J. Contos, R. K. Sterling, M. Fuchs, H. Zhou, et al. 2009. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 50 : 1827-1838.
14. Feldstein, A. E., R. Lopez, T. A. Tamimi, L. Yeian, Y. M. Chung, M. Berk, R. Zhang, T. M. McIntyre, and S. L. Hazen. 2010. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51 : 3046-3054.
15. Barr, J., M. Vazquez-Chantada, C. Alonso, M. Perez-Cormenzana, R. Mayo, A. Galan, J. Caballeria, A. Martin-Duce, A. Tran, C. Wagner, et al. 2010. Liquid chromatography-mass spectrometry-based parallel metabolic profi ling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9 : 4501-4512.
16. Pagadala, M., T. Kasumov, A. J. McCullogh, N. N. Zein, and J. P. Kirwan. 2012. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 23 : 365-371.
17. Musso, G., R. Gambino, F. De Michieli, M. Durazzo, G. Pagano, and M. Cassader. 2008. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology. 47 : 1167-1177.
18. Smagris, E., S. BasuRay, J. Li, Y. Huang, K. M. Lai, J. Gromada, J. C. Cohen, and H. H. Hobbs. 2015. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 61 : 108-118.
19. Kleiner, D. E., E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, et al Nonalcoholic Steatohepatitis Clinical Research Network. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41 : 1313-1321.
20. Ivanova, P. T., S. B. Milne, M. O. Byrne, Y. Xiang, and H. A. Brown. 2007. Glycerophospholipid identification and quantitation by electrospray ionization mass spectrometry. Methods Enzymol. 432 : 21-57.
21. Myers, D. S., P. T. Ivanova, S. B. Milne, and H. A. Brown. 2011. Quantitative analysis of glycerophospholipids by LC-MS: acquisition, data handling, and interpretation. Biochim. Biophys. Acta. 1811 : 748-757.
22. Quehenberger, O., A. M. Armando, H. A. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, Jr., S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51 : 3299-3305.
23. Guan, Z., S. Li, D. Smith, W. Shaw, and C. Raetz. 2007. Identification of N-acylphosphatidylserine molecules in eukaryotic cells. Biochemistry. 46 : 14500-14513.
24. Tan, B. K., M. Bogdanov, J. Zhao, W. Dowhan, C. R. Raetz, and Z. Guan. 2012. Discovery of cardiolipin synthase utilizing phosphatidylethanolamine and phosphatidylglycerol as substrates. Proc. Natl. Acad. Sci. USA. 109 : 16504-16509.
25. Wen, R., B. Lam, and Z. Guan. 2013. Aberrant dolichol chain lengths as biomarkers for retinitis pigmentosa caused by impaired dolichol biosynthesis. J. Lipid Res. 54 : 3516-3522.
26. Quehenberger, O., A. Armando, D. Dumlao, D. L. Stephens, and E. A. Dennis. 2008. Lipidomics analysis of essential fatty acids in macrophages. Prostaglandins Leukot. Essent. Fatty Acids. 79 : 123-129.
27. Quehenberger, O., A. M. Armando, and E. A. Dennis. 2011. High sensitivity quantitative lipidomics analysis of fatty acids in biological samples by gas chromatography-mass spectrometry. Biochim. Biophys. Acta. 1811 : 648-656.
28. Deems, R., M. W. Buczynski, R. Bowers-Gentry, R. Harkewicz, and E. A. Dennis. 2007. Detection and quantitation of eicosanoids via high performance liquid chromatography-electrospray ionizationmass spectrometry. Methods Enzymol. 432 : 59-82.
29. Dumlao, D. S., M. W. Buczynski, P. C. Norris, R. Harkewicz, and E. A. Dennis. 2011. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim. Biophys. Acta. 1811 : 724-736.
30. McDonald, J. G., D. D. Smith, A. R. Stiles, and D. W. Russell. 2012. A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J. Lipid Res. 53 : 1399-1409.
31. Hutchins, P. M., R. M. Barkley, and R. C. Murphy. 2008. Separation of cellular nonpolar neutral lipids by normal-phase chromatography and analysis by electrospray ionization mass spectrometry. J. Lipid Res. 49 : 804-813.
32. Shaner, R. L., J. C. Allegood, H. Park, E. Wang, S. Kelly, C. A. Haynes, M. C. Sullards, and A. H. Merrill, Jr. 2009. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J. Lipid Res. 50 : 1692-1707.
33. Sullards, M. C., Y. Liu, Y. Chen, and A. H. Merrill, Jr. 2011. Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry (LC-MS/MS) and tissue imaging mass spectrometry (TIMS). Biochim. Biophys. Acta. 1811 : 838-853.
34. Wang, Y., A. M. Armando, O. Quehenberger, C. Yan, and E. A. Dennis. 2014. Comprehensive ultra-performance liquid chromatographic separation and mass spectrometric analysis of eicosanoid metabolites in human samples. J. Chromatogr. A. 1359 : 60-69.
35. Leiker, T. J., R. M. Barkley, and R. C. Murphy. 2011. Analysis of diacylglycerol molecular species in cellular lipid extracts by normal-phase LC-electrospray mass spectrometry. Int. J. Mass Spectrom. 305 : 103-109.
36. Zitomer, N. C., T. Mitchell, K. A. Voss, G. S. Bondy, S. T. Pruett, E. C. Garnier-Amblard, L. S. Liebeskind, H. Park, E. Wang, M. C. Sullards, et al. 2009. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J. Biol. Chem. 284 : 4786-4795.
37. Coulier, L., R. Bas, S. Jespersen, E. Verheij, M. J. van der Werf, and T. Hankemeier. 2006. Simultaneous quantitative analysis of metabolites using ion-pair liquid chromatography - electrospray ionization mass spectrometry. Anal. Chem. 78 : 6573-6582.
38. Fromentin, E., C. Gavegnano, A. Obikhod, and R. Schinazi. 2010. Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography- tandem mass spectrometry. Anal. Chem. 82 : 1982-1989.
39. Heinz, S., C. E. Romanoski, C. Benner, K. A. Allison, M. U. Kaikkonen, L. D. Orozco, and C. K. Glass. 2013. Effect of natural genetic variation on enhancer selection and function. Nature. 503 : 487-492.
40. Hu, J., H. Ge, M. Newman, and K. Liu. 2012. OSA: a fast and accurate alignment tool for RNA-Seq. Bioinformatics. 28 : 1933-1934.
41. Anders, S., and W. Huber. 2010. Differential expression analysis for sequence count data. Genome Biol. 11 : R106.
42. Huang da, W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37 : 1-13.
43. Huang da, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 : 44-57.
44. Subramaniam, S., and G. Hsiao. 2012. Gene expression measurement: variance-modeling considerations for robust data analysis. Nat. Immunol. 13 : 199-203.
45. Pico, A. R., T. Kelder, M. P. van Iersel, K. Hanspers, B. R. Conclin, and C. Evelo. 2008. WikiPathways: pathway editing for the people. PLoS Biol. 6 : e184.
46. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. Ferreira, D. Bender, J. Maller, P. Sklar, P. I. de Bakker, M. J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81 : 559-575.
47. Gorden, D. L., P. T. Ivanova, D. S. Myers, J. O. McIntyre, M. N. VanSaun, J. K. Wright, L. M. Matrisian, and H. A. Brown. 2011. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS ONE. 6 : e22775.
48. Garcia-Cañaveras, J. C., M. T. Donato, J. V. Castell, and A. Lahoz. 2011. A comprehensive untargeted metabolomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. J. Proteome Res. 10 : 4825-4834.
49. Lake, A. D., P. Novak, C. D. Fisher, J. P. Jackson, R. N. Hardwick, D. D. Billheimer, W. T. Klimetcki, and N. J. Cherrington. 2011. Analysis of global and absorption, distribution, metabolism, and eliminaton gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39 : 1954-1960.
50. Lake, A. D., P. Novak, R. N. Hardwick, B. Flores-Keown, F. Zhao, W. T. Klimecki, and N. J. Cherrington. 2014. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicol. Sci. 137 : 26-35.
51. Younossi, Z. M., F. Gorreta, J. P. Ong, K. Schlauch, L. Del Giacco, H. Elariny, A. VanMeter, A. Younoszai, Z. Goodman, A. Baranova, et al. 2005. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 25 : 760-771.
52. Younossi, Z. M., A. Baranova, K. Ziegler, L. Del Giacco, K. Schlauch, T. L. Born, H. Elariny, F. Gorreta, A. VanMeter, A. Younoszai, et al. 2005. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 42 : 665-674.
53. Romeo, S., J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L. A. Pennacchio, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40 : 1461-1465.
54. Merrill, A. H., Jr. 2011. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 111 : 6387-6422.
55. Zuellig, R. A., T. Hornemann, A. Othman, A. B. Hehl, H. Bode, T. Güntert, O. O. Ogunshola, E. Saponara, K. Grabliauskaite, J. H. Jang, et al. 2014. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. Diabetes. 63 : 1326-1339.
56. Jiménez-Rojo, N., J. Sot, J. V. Busto, W. A. Shaw, J. Duan, A. H. Merrill, Jr., A. Alonso, and F. M. Goñi. 2014. Biophysical properties of novel 1-deoxy-(dihydro)ceramides occurring in mammalian cells. Biophys. J. 107 : 2850-2859.
57. Watt, M. J., A. C. Barnett, C. R. Bruce, S. Schenk, J. F. Horowitz, and A. J. Hoy. 2012. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesized ceramide. Diabetologia. 55 : 2741-2746.
58. Merrill, A. H., Jr., S. Lingrell, E. Wang, M. Nikolova-Karakashian, T. R. Vales, and D. E. Vance. 1995. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. J. Biol. Chem. 270 : 13834-13841.
59. McGettrick, A. F., and L. A. O'Neill. 2013. How metabolism generates signals during innate immunity and inflammation. J. Biol. Chem. 288 : 22893-22898.
60. Schleicher, J., R. Gutke, U. Dahmen, O. Dirsch, H. G. Holzhuetter, and S. Schuster. 2014. A theoretical study of lipid accumulation in the liver-implications for nonalcoholic fatty liver disease. Biochim. Biophys. Acta. 1841 : 62-69.
61. Mantena, S. K., D. P. Vaughn, K. K. Andringa, H. B. Eccleston, A. L. King, G. A. Abrams, J. E. Doeller, D. W. Kraus, V. M. Darley-Usmar, and S. M. Bailey. 2009. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem. J. 417 : 183-193.
62. Qu, A., M. Taylor, X. Xue, T. Matsubara, D. Metzger, P. Chambon, F. J. Gonzalez, and Y. M. Shah. 2011. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology. 54 : 472-483.
63. Wong, R. J., R. Cheung, and A. Ahmed. 2014. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology. 59 : 2188-2195.
64. Ridgeway, N. D. 2013. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit. Rev. Biochem. Mol. Biol. 48 : 20-38.
65. Ide, Y., M. Waki, T. Hayasaka, T. Nishio, Y. Morita, H. Tanaka, T. Sasaki, K. Koizumi, R. Matsunuma, Y. Hosokawa, et al. 2013. Human breast cancer tissues contain abundant phosphatidylcholine (36:1) with high stearoyl-CoA desaturase-1 expression. PLoS ONE. 8 : e61204.
66. Kennedy, E. P. 1987. Metabolism and function of membrane lipids. Klin. Wochenschr. 65 : 205-212.
67. Smith, R. E., P. Lespi, M. Di Luca, C. Bustos, F. A. Marra, M. J. de Alaniz, and C. A. Marra. 2008. A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers. Lipids. 43 : 79-89.
68. Wree, A., M. D. McGeough, C. A. Peña, M. Schlattjan, H. Li, M. E. Inzaugarat, K. Messer, A. Canbay, H. M. Hoffman, and A. E. Feldstein. 2014. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. (Berl). 92 : 1069-1082.
69. Friedman, S. L. 2013. Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH. Nat. Rev. Gastroenterol. Hepatol. 10 : 71-72.